Comparison of 99m Tc-methylenediphosphonate and 68 Ga-BPAMD PET/computed tomography imaging in bone metastasis.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
medline:
12
5
2023
pubmed:
11
3
2023
entrez:
10
3
2023
Statut:
ppublish
Résumé
Bone is considered as the third most common site of metastases, besides lung and liver. Early detection of skeletal metastases aids in better management of skeletal-related events. In the present study cold kit-based 2,2 ' ,2 '' -(10-(2-((diphosphonomethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (BPAMD) was labeled with 68 Ga. The radiolabeling parameters and clinical evaluation in patients with suspected bone metastases were compared with routinely used 99m Tc-methylenediphosphonate ( 99m Tc-MDP). The kit components of MDP were incubated with at room temperature for 10 min, followed by radiochemical purity testing using thin-layer chromatography. For radiolabeling of BPAMD, the cold kit components reconstituted in 400 μL of HPLC grade water were transferred and incubated with 68 GaCl 3 in the reactor vessel of the fluidic module at 95°C for 20 min. Radiochemical yield and purity were determined with instant thin-layer chromatography using 0.5 M sodium citrate as mobile phase. For clinical evaluation, patients ( n = 10) with suspected bone metastases were enrolled. 99m Tc-MDP and 68 Ga-BPAMD scans were performed on two different days in random order. Imaging outcomes were noted and compared. Radiolabeling of both tracers is facile using cold kit, although BPAMD requires heating. The radiochemical purity was observed to be greater than 99% for all preparations. Both MDP and BPAMD detected skeletal lesions; however, additional lesions were detected in total of seven patients which were not visualized clearly on 99m Tc-MDP scan. BPAMD can be easily tagged with 68 Ga using cold kits. The radiotracer is suitable and efficient for detection of bone metastases using PET/computed tomography.
Identifiants
pubmed: 36897059
doi: 10.1097/MNM.0000000000001685
pii: 00006231-202306000-00007
doi:
Substances chimiques
methylene diphosphonate
73OS0QIN3O
Diphosphonates
0
Radiopharmaceuticals
0
Gallium-68
98B30EPP5S
Technetium Tc 99m Medronate
X89XV46R07
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-470Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Coleman R. Metastatic bone disease: clinical features, patho-physiology and treatment strategies. Cancer Treat Rev 2001; 27:165–176.
Agarwal MG, Nayak P. Management of skeletal metastases: an orthopaedic surgeon’s guide. Indian J Orthop 2015; 49:83–100.
Cecchini M, Wetterwald A, Plum G, Thalmann G. Molecular and biological mechanisms of bone metastasis. EAU Update Series 2005; 3:214–226.
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: an overview. Oncol Rev 2017; 11:321–327.
Selvaggi G, Scagliotti G. Management of bone metastases in cancer: a review. Clin Rev Oncol Hematol 2005; 56:365–378.
Lukaszewski B, Nazar J, Goch M, Łukaszewska M, Stepinski A, Jurczyk MU.Contemp Oncol 2017; 21:98–103.
Coleman R, Body J, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014; 25:iii124–iii137.
Ziessman HA, O’Malley J, Thrall JH. Nuclear medicine: the requisites. 4th ed. Elsevier Saunders; 2014.
Harmer CL, Burns JE, Sams A, Spittle M. The value of fluorine-18 for scanning bone tumours. Clin Radiol 1969; 20:204–212.
Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med 2006; 36:286–294.
Cook GJ, Azad G, Padhani AR. Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging 2016; 4:439–447.
Almuhaideb A, Papathanasiou N, Bomanji J. 18 F-FDG PET/CT imaging in oncology. Ann Saudi Med 2011; 31:3–13.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:6116–6177.
Kesch C, Kratochwil C, Mier W, Klaus K, Giesel FL. Gallium-68 or fluorine-18 for prostate cancer imaging? J Nucl Med 2017; 58:687–688.
Banerjee SR, Pomper MG. Clinical applications of gallium-68. Appl Radiat Isot 2013; 76:2–13.
Meckel M, Fellner M, Thieme N, Bergman R, Kubicek V, Rösch F. In vivo comparison of DOTA based 68 Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nucl Med Biol 2013; 40:823–830.
Kálmán FK, Király R, Brücher E. Stability constants and dissociation rates of the EDTMP complexes of samarium(III) and yttrium(III). Eur J Inorg Chem 2008; 30:4719–4727.
Fellner M, Riss P, Loktionova NS, Zhernosekov KP, Thews O, Geraldes CFGC, et al. Comparison of different phosphorus-containing ligands complexing 68 Ga for PET-imaging of bone metabolism. Radiochim Acta 2011; 99:43–51.
Chopra A. 68Ga-labeled (4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid (BPAMD). In: Molecular imaging and contrast agent database (MICAD) [Internet]. National Center for Biotechnology Information (US); 2012 [updated 21 November 2012]. pp. 2004–2013.
Fellner M, Baum RP, Kubicek V, Hermann P, Lukes I, Prasad V, et al. PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010; 37:834.
Fellner M, Biesalski B, Bausbacher N, Kubicek V, Hermann P, Rosch F, et al. 68 Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012; 39:993–999.
Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A. Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application. Nucl Med Commun 2010; 31:753–758.
Nelson BJB, Andersson JD, Wuest F, Spreckelmeyer S. Good practices for 68 Ga radiopharmaceutical production. EJNMMI Radiopharm Chem 2022; 7:27.
Vatsa R, Bhusari P, Kumar S, Chakraborty S, Dash A, Singh G, et al. Integrin αvβ3 as a promising target to image neoangiogenesis using in-house generator-produced positron emitter (68)Ga-labeled DOTA-arginine-glycine-aspartic acid (RGD) ligand. Cancer Biother Radiopharm 2015; 30:217–224.
Peller PJ, Ho VB, Kransdorf MJ. Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. Radiographics 1993; 13:715–734.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032–1045.
Pauwels EK, Stokkel MP. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice. Q J Nucl Med 2001; 45:18–26.
Pfannkuchen N, mocked M, Sathekge M, Mohnike W, Roesch F. DOTAZOL as novel bone seeking compound for Ga-68 PET diagnosis and Lu-177 endoradiotherapy of bone metastases: from preclinical to first human results. J Nucl Med 2016; 57:472.
Meckel M, Nauth A, Timpe J, Zhernosekov K, Puranik AD, Baum RP, et al. Development of a [ 177 Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy. Cancer Biother Radiopharm 2015; 30:94–99.
Fellner M, Baum R, Kubicek V, Hermann P, Roesch F. 177 Lu-BPAMD – from bone imaging to therapy with a macrocycle-bisphosphonate ligand. J Nucl Med 2010; 51:1164.
Chakraborty S, Das S, Chakravarty R, Shetty P, Vatsa R, Shukla J, et al. Formulation and evaluation of human clinical doses of 177 Lu-labeled bisphosphonate amide of DOTA using lyophilized kits. Nucl Med Biol 2021; 96-97:S99–S100.